靶向Her2的肿瘤治疗性抗体研究进展

Progress in the study of Her2-targeted cancer therapeutic antibodies

肿瘤表面抗原人表皮生长因子受体2(Her2)是一种I型受体酪氨酸激酶,属于表皮生长因子受体家族,其过表达与肿瘤发生及转移密切相关。由于临床效果显著,Her2靶向肿瘤治疗尤其是治疗性抗体成为肿瘤治疗领域的研究热点。靶向Her2的抗体药物主要有单克隆抗体、抗体偶联药物、双特异抗体及新型"二合一"抗体等,本文基于Her2的结构功能,综述了这些抗体的作用机制与临床研究进展。

Tumor surface antigen human epidermal growth factor receptor 2 （Her2） is a type I receptor tyrosine kinase, which belongs to human epidermal growth factor receptor family. Her2-overexpression is associated with tumorigenesis and metastasis. Due to significant clinical effects, Her2-targeted cancer therapy especially therapeutic antibody has become the hot spot in the field of cancer treatment. Anti-Her2 antibody drugs include monoclonal antibodies, antibody-drug conjugates, bispecific antibodies and emerging ＂two in one＂ antibody. Based on structure and function of Her2, this review focuses on recent advances in active mechanisms and clinical researches of these antibodies.